Health Care & Life Sciences » Biotechnology | Celldex Therapeutics Inc.

Celldex Therapeutics Inc.

Celldex Therapeutics Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
162.44 M
Public Float
142.74 M
Celldex Therapeutics Inc.
Stock Exchange NASDAQ Stock Market
EPS
$4.52
Market Cap
$31.62 M
Shares Outstanding
13.77 M
Public Float
12.07 M

Profile

Address
Perryville III Building
Hampton New Jersey 08827
United States
Employees -
Website http://www.celldex.com
Updated 09/14/2018
Celldex Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes therapeutic antibodies, antibody drug conjugates, vaccines, and immune system modulators. The company's drug candidates include Glembatumumab vedotin, Varlilumab, CDX-1401, CDX-301, and Rintega.

Financials

View All

Anthony S. Marucci
President, Chief Executive Officer & Director
Herbert J. Conrad
Director